Nothing Special   »   [go: up one dir, main page]

SE8304818L - MEDICINE WITH ANTICULAR, SPASMOLYTIC AND LOCAL ANESTIC EFFECTS - Google Patents

MEDICINE WITH ANTICULAR, SPASMOLYTIC AND LOCAL ANESTIC EFFECTS

Info

Publication number
SE8304818L
SE8304818L SE8304818A SE8304818A SE8304818L SE 8304818 L SE8304818 L SE 8304818L SE 8304818 A SE8304818 A SE 8304818A SE 8304818 A SE8304818 A SE 8304818A SE 8304818 L SE8304818 L SE 8304818L
Authority
SE
Sweden
Prior art keywords
spasmolytic
local
anticular
anestic
medicine
Prior art date
Application number
SE8304818A
Other languages
Swedish (sv)
Other versions
SE8304818D0 (en
SE462420B (en
Inventor
L Benes
A Babulova
V Nosalova
S Stolc
A Borovansky
V Bauer
Original Assignee
Slovenska Akademia Vied
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Slovenska Akademia Vied filed Critical Slovenska Akademia Vied
Publication of SE8304818D0 publication Critical patent/SE8304818D0/en
Publication of SE8304818L publication Critical patent/SE8304818L/en
Publication of SE462420B publication Critical patent/SE462420B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to pharmaceutical compositions with antiulcer, spasmolytic and local anaesthetic action, which are particularly suitable for oral administration and contain as active ingredient trans-2-(1-pyrrolidinyl)cyclohexyl 3-n-pentyloxycarbanilate or one of its salts with a pharmaceutically suitable inorganic or organic acid and, preferably, the corresponding hydrochloride, together with a physiologically acceptable vehicle and/or an antacid component. The compositions according to the invention prevent at a daily dose of 10 to 200 mg the formation of tumours, inhibit their spread and shorten the duration of healing, the dosage being less than with conventional compositions having the same action. Combination of the active ingredient with antacid substances is particularly advantageous.
SE8304818A 1983-09-13 1983-09-08 APPLICATION OF TRANS-2- (1-PYRROLIDINYL) -CYCLOHEXYL ESTER OF 3-N-PENTYLOXICARBANIC ACID FOR PREPARATION OF A MEDICINAL PRODUCT WITH AN ANGENTIC EFFECT SE462420B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833333008 DE3333008A1 (en) 1983-09-13 1983-09-13 Pharmaceutical compositions with antiulcer, spasmolytic and local anaesthetic action

Publications (3)

Publication Number Publication Date
SE8304818D0 SE8304818D0 (en) 1983-09-08
SE8304818L true SE8304818L (en) 1985-03-09
SE462420B SE462420B (en) 1990-06-25

Family

ID=6208945

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8304818A SE462420B (en) 1983-09-13 1983-09-08 APPLICATION OF TRANS-2- (1-PYRROLIDINYL) -CYCLOHEXYL ESTER OF 3-N-PENTYLOXICARBANIC ACID FOR PREPARATION OF A MEDICINAL PRODUCT WITH AN ANGENTIC EFFECT

Country Status (6)

Country Link
JP (1) JPS6067421A (en)
BE (1) BE897823A (en)
CH (1) CH654743A5 (en)
DE (1) DE3333008A1 (en)
NL (1) NL8303098A (en)
SE (1) SE462420B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103380A (en) 1998-06-03 2000-08-15 Cabot Corporation Particle having an attached halide group and methods of making the same

Also Published As

Publication number Publication date
DE3333008A1 (en) 1985-03-21
CH654743A5 (en) 1986-03-14
SE8304818D0 (en) 1983-09-08
SE462420B (en) 1990-06-25
NL8303098A (en) 1985-04-01
JPS6067421A (en) 1985-04-17
JPH045003B2 (en) 1992-01-30
DE3333008C2 (en) 1990-06-21
BE897823A (en) 1984-01-16

Similar Documents

Publication Publication Date Title
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
ES2170069T3 (en) 1-ALFA-HYDROXIPREVITAMINE D FOR ORAL ADMINISTRATION.
ES2188782T3 (en) PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACINE.
ES2171469T3 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT.
RU95107881A (en) Pharmaceutical composition for allergic disease treatment, method of antihistamine treatment, use of composition for medicinal preparation preparing
RU98111594A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU94046316A (en) Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment
ES2074513T3 (en) USE OF AN OPIACEOUS ANTAGONIST FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TRANSDERMIC ADMINISTRATION AND A DEVICE FOR PERCUTANEOUS SUPPLY.
IS4396A (en) inhalation Compounds
ATE99172T1 (en) USE OF ACETYL-L-CARNITINE IN TREATMENT OF CATARACT, AND PHARMACEUTICAL COMPOSITIONS FOR SUCH TREATMENT.
KR970061244A (en) Pharmaceutical composition for treating dementia
RU95101385A (en) Products containing g-csf and tnf-binding protein
ES2119748T3 (en) PHARMACEUTICAL COMPOSITION CONTAINING A PHARMACEUTICALLY SOLUBLE IN WATER.
ES2175663T3 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS.
ES8307496A1 (en) Galenic preparation.
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
KR890004705A (en) Antiviral agents
ATE13488T1 (en) GALLIUM CHLORIDE, A NEW ANTI-CANCER AGENT.
SE8304818L (en) MEDICINE WITH ANTICULAR, SPASMOLYTIC AND LOCAL ANESTIC EFFECTS
DE3688787D1 (en) PRODUCTION OF A MEDICINE AGAINST ARTHRITIS AND RHEUMATISM.
RU2678821C1 (en) Pharmaceutical composition for the treatment of oral cavity diseases with anti-inflammatory and anti-bacterial actions
AR002946A1 (en) A SET FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOPOROSIS IN MAMMALS ACCORDING TO A CYCLIC DIET.
KR830008678A (en) Analgesic composition
KR890001558A (en) Zephyron and its pharmaceutically acceptable acid addition salts alleviate panic disorder

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8304818-1

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8304818-1

Format of ref document f/p: F